Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study

Background: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies...

Full description

Bibliographic Details
Main Authors: Antonio Muro, Moncef Belhassen-García, Juan Luís Muñoz Bellido, Helena Lorenzo Juanes, Belén Vicente, Josué Pendones, José Adserias, Gonzalo Sánchez Hernández, Miguel Rodríguez Rosa, José Luis Vicente Villardón, Javier Burguillo, Javier López Andaluz, Jose Angel Martín Oterino, Francisco Javier García Criado, Fausto Barbero, Ana Isabel Morales, Purificación Galindo Villardón, Rogelio González Sarmiento, on behalf of the DIANCUSAL Team
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/10/15/3214
id doaj-997ea0974b1e43c584a1a18cd994db4f
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Antonio Muro
Moncef Belhassen-García
Juan Luís Muñoz Bellido
Helena Lorenzo Juanes
Belén Vicente
Josué Pendones
José Adserias
Gonzalo Sánchez Hernández
Miguel Rodríguez Rosa
José Luis Vicente Villardón
Javier Burguillo
Javier López Andaluz
Jose Angel Martín Oterino
Francisco Javier García Criado
Fausto Barbero
Ana Isabel Morales
Purificación Galindo Villardón
Rogelio González Sarmiento
on behalf of the DIANCUSAL Team
spellingShingle Antonio Muro
Moncef Belhassen-García
Juan Luís Muñoz Bellido
Helena Lorenzo Juanes
Belén Vicente
Josué Pendones
José Adserias
Gonzalo Sánchez Hernández
Miguel Rodríguez Rosa
José Luis Vicente Villardón
Javier Burguillo
Javier López Andaluz
Jose Angel Martín Oterino
Francisco Javier García Criado
Fausto Barbero
Ana Isabel Morales
Purificación Galindo Villardón
Rogelio González Sarmiento
on behalf of the DIANCUSAL Team
Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
Journal of Clinical Medicine
SARS-CoV-2
COVID-19
antibodies
seroprevalence
screening
university
author_facet Antonio Muro
Moncef Belhassen-García
Juan Luís Muñoz Bellido
Helena Lorenzo Juanes
Belén Vicente
Josué Pendones
José Adserias
Gonzalo Sánchez Hernández
Miguel Rodríguez Rosa
José Luis Vicente Villardón
Javier Burguillo
Javier López Andaluz
Jose Angel Martín Oterino
Francisco Javier García Criado
Fausto Barbero
Ana Isabel Morales
Purificación Galindo Villardón
Rogelio González Sarmiento
on behalf of the DIANCUSAL Team
author_sort Antonio Muro
title Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
title_short Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
title_full Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
title_fullStr Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
title_full_unstemmed Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
title_sort seroprevalence of sars-cov-2 antibodies and factors associated with seropositivity at the university of salamanca: the diancusal study
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2021-07-01
description Background: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. Objective: The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. Methodology: The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July–October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. Principal findings: A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (<i>p</i> = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (<i>p</i> = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (<i>p</i> = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. Conclusions: The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.
topic SARS-CoV-2
COVID-19
antibodies
seroprevalence
screening
university
url https://www.mdpi.com/2077-0383/10/15/3214
work_keys_str_mv AT antoniomuro seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT moncefbelhassengarcia seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT juanluismunozbellido seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT helenalorenzojuanes seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT belenvicente seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT josuependones seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT joseadserias seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT gonzalosanchezhernandez seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT miguelrodriguezrosa seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT joseluisvicentevillardon seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT javierburguillo seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT javierlopezandaluz seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT joseangelmartinoterino seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT franciscojaviergarciacriado seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT faustobarbero seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT anaisabelmorales seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT purificaciongalindovillardon seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT rogeliogonzalezsarmiento seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
AT onbehalfofthediancusalteam seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy
_version_ 1721218178347958272
spelling doaj-997ea0974b1e43c584a1a18cd994db4f2021-08-06T15:26:28ZengMDPI AGJournal of Clinical Medicine2077-03832021-07-01103214321410.3390/jcm10153214Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL StudyAntonio Muro0Moncef Belhassen-García1Juan Luís Muñoz Bellido2Helena Lorenzo Juanes3Belén Vicente4Josué Pendones5José Adserias6Gonzalo Sánchez Hernández7Miguel Rodríguez Rosa8José Luis Vicente Villardón9Javier Burguillo10Javier López Andaluz11Jose Angel Martín Oterino12Francisco Javier García Criado13Fausto Barbero14Ana Isabel Morales15Purificación Galindo Villardón16Rogelio González Sarmiento17on behalf of the DIANCUSAL TeamInfectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainInfectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainInfectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainIT Department, University of Salamanca Foundation (FGUSAL), University of Salamanca, 37008 Salamanca, SpainData Processing Center (CPD), University of Salamanca, 37008 Salamanca, SpainDepartment of Statistics, University of Salamanca, 37008 Salamanca, SpainDepartment of Statistics, University of Salamanca, 37008 Salamanca, SpainDepartment of Chemistry-Physics, Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainDepartment of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainDepartment of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainDepartment of Statistics, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainBackground: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. Objective: The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. Methodology: The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July–October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. Principal findings: A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (<i>p</i> = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (<i>p</i> = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (<i>p</i> = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. Conclusions: The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.https://www.mdpi.com/2077-0383/10/15/3214SARS-CoV-2COVID-19antibodiesseroprevalencescreeninguniversity